Latest news with #ImportAlert
Business Upturn
25-05-2025
- Business
- Business Upturn
VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)
NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al. , No. 25-cv-466. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in 'good operating condition,' were 'suitable for their intended purposes,' and that the Company was 'committed to maintaining the highest quality manufacturing standards.' However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the situation, describing it as a 'little bit of headwind' and spoke about 'active discussions with the FDA' to get additional products produced at the facility exempted from the FDA's Import Alert. In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company's financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide. The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the 'negative impact' of the Indore facility's failed inspection would lower 2025 revenue by 'approximately $500 million' and 2025 earnings from operations by 'approximately $385 million.' The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025. Click here if you suffered losses: What Can You Do? If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Associated Press
21-05-2025
- Business
- Associated Press
VTRS LAWSUIT: Lose Money on Viatris Inc.? Contact BFA Law before June 3 Court Deadline
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al., No. 25-cv-466. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in 'good operating condition,' were 'suitable for their intended purposes,' and that the Company was 'committed to maintaining the highest quality manufacturing standards.' However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the situation, describing it as a 'little bit of headwind' and spoke about 'active discussions with the FDA' to get additional products produced at the facility exempted from the FDA's Import Alert. In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company's financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide. The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the 'negative impact' of the Indore facility's failed inspection would lower 2025 revenue by 'approximately $500 million' and 2025 earnings from operations by 'approximately $385 million.' The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025. Click here if you suffered losses: What Can You Do? If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Business Upturn
17-05-2025
- Business
- Business Upturn
VTRS SHAREHOLDER NEWS: Investors of Viatris Inc. Securities are Reminded of the June 3 Class Action Deadline — Contact BFA Law (NASDAQ:VTRS)
NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al. , No. 25-cv-466. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in 'good operating condition,' were 'suitable for their intended purposes,' and that the Company was 'committed to maintaining the highest quality manufacturing standards.' However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the situation, describing it as a 'little bit of headwind' and spoke about 'active discussions with the FDA' to get additional products produced at the facility exempted from the FDA's Import Alert. In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company's financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide. The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the 'negative impact' of the Indore facility's failed inspection would lower 2025 revenue by 'approximately $500 million' and 2025 earnings from operations by 'approximately $385 million.' The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025. Click here if you suffered losses: What Can You Do? If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Associated Press
29-04-2025
- Business
- Associated Press
VTRS ALERT: Viatris Inc. (NASDAQ:VTRS) Investors are Reminded of Pending Securities Fraud Class Action – Contact BFA Law by June 3 Deadline
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al., No. 25-cv-466. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in 'good operating condition,' were 'suitable for their intended purposes,' and that the Company was 'committed to maintaining the highest quality manufacturing standards.' However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the situation, describing it as a 'little bit of headwind' and spoke about 'active discussions with the FDA' to get additional products produced at the facility exempted from the FDA's Import Alert. In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company's financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide. The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the 'negative impact' of the Indore facility's failed inspection would lower 2025 revenue by 'approximately $500 million' and 2025 earnings from operations by 'approximately $385 million.' The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025. Click here if you suffered losses: What Can You Do? If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Yahoo
28-03-2025
- Health
- Yahoo
FDA bars Chinese seafood companies from doing business in US after disturbing discovery found in imported clams — here's what it found
The U.S. Food and Drug Administration in February announced that eight Chinese seafood companies were added to its Import Alert list. The action followed the discovery of concerning levels of per- and polyfluoroalkyl substances in imported clams. The affected clams contain alarming levels of the toxic PFAS. The FDA issued a warning to the barred seafood companies. Any attempt to enter the U.S. will lead to automatic detention at the border, without any physical inspection. This helps ensure that the contaminated seafood doesn't make it to supermarkets. Known as "forever chemicals," PFAS are found in many industrial and everyday products. However, their presence in food and the environment can lead to severe health problems. Elevated exposure to certain PFAS has been linked to cancer, liver damage, pre-eclampsia, and high blood pressure, per the FDA. Polluted water is the culprit for clam contamination. The National Library of Medicine reported that shellfish has the highest PFAS level. Chemical concentrations in clams, mussels, and crabs are higher than PFAS found in fish, beef, and pork. This can negatively impact regions and communities that rely on the seafood industry to boost local economies. This isn't the first time food imports have been subject to review. Produce imported into the United Kingdom has been found with harmful pesticides not approved for use by British farmers. The Import Alert helps ensure that consumers can trust the food they buy and won't have to make a trip to the hospital. Other rules, such as banning fisheries that don't meet U.S. bycatch standards, make trade agreements more ethical and long-lasting. Consumers can also be proactive in lowering their PFAS exposure by staying informed about food safety alerts from reputable agencies and making smart grocery choices. Proper food preparation is also important — washing apples, for instance, doesn't fully remove pesticide residue on their skin. Do you worry about having toxic forever chemicals in your home? Majorly Sometimes Not really I don't know enough about them Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
